Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8527 |
High Similarity |
NPD3027 |
Phase 3 |
0.8475 |
Intermediate Similarity |
NPD3022 |
Approved |
0.8475 |
Intermediate Similarity |
NPD3021 |
Approved |
0.8195 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8195 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8092 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.803 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7971 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7955 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7903 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7842 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7742 |
Intermediate Similarity |
NPD228 |
Approved |
0.7712 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7682 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7669 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7664 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7664 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7634 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7634 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.763 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7586 |
Intermediate Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.7519 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7518 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD6190 |
Approved |
0.75 |
Intermediate Similarity |
NPD3092 |
Approved |
0.7458 |
Intermediate Similarity |
NPD2859 |
Approved |
0.7458 |
Intermediate Similarity |
NPD2860 |
Approved |
0.7434 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7434 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7434 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.741 |
Intermediate Similarity |
NPD3062 |
Approved |
0.741 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.741 |
Intermediate Similarity |
NPD3059 |
Approved |
0.741 |
Intermediate Similarity |
NPD3061 |
Approved |
0.7388 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7373 |
Intermediate Similarity |
NPD2933 |
Approved |
0.7373 |
Intermediate Similarity |
NPD2934 |
Approved |
0.7361 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7357 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7355 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7348 |
Intermediate Similarity |
NPD9384 |
Approved |
0.7348 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7348 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7348 |
Intermediate Similarity |
NPD9381 |
Approved |
0.7342 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7328 |
Intermediate Similarity |
NPD3091 |
Approved |
0.7328 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7324 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7305 |
Intermediate Similarity |
NPD5314 |
Approved |
0.7303 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7286 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7279 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7259 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7259 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7244 |
Intermediate Similarity |
NPD9280 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7241 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7237 |
Intermediate Similarity |
NPD37 |
Approved |
0.7237 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7234 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7231 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7222 |
Intermediate Similarity |
NPD2684 |
Approved |
0.72 |
Intermediate Similarity |
NPD968 |
Approved |
0.7192 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7185 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7174 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7165 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7163 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7133 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7133 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7133 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7132 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7132 |
Intermediate Similarity |
NPD9622 |
Approved |
0.7132 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7123 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7123 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7113 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7111 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7101 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7099 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7097 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7095 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.709 |
Intermediate Similarity |
NPD3095 |
Discontinued |
0.7083 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7083 |
Intermediate Similarity |
NPD1432 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7078 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7075 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7075 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7075 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7071 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7068 |
Intermediate Similarity |
NPD7741 |
Discontinued |
0.7059 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7059 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.705 |
Intermediate Similarity |
NPD5736 |
Approved |
0.7047 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7034 |
Intermediate Similarity |
NPD2161 |
Phase 2 |
0.7029 |
Intermediate Similarity |
NPD4339 |
Clinical (unspecified phase) |
0.7027 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7025 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7021 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7021 |
Intermediate Similarity |
NPD2028 |
Clinical (unspecified phase) |
0.7019 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7016 |
Intermediate Similarity |
NPD940 |
Approved |
0.7016 |
Intermediate Similarity |
NPD846 |
Approved |
0.7007 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7 |
Intermediate Similarity |
NPD9379 |
Approved |
0.7 |
Intermediate Similarity |
NPD9377 |
Approved |
0.7 |
Intermediate Similarity |
NPD7635 |
Approved |
0.6992 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6988 |
Remote Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.6986 |
Remote Similarity |
NPD5762 |
Approved |
0.6986 |
Remote Similarity |
NPD5763 |
Approved |
0.6986 |
Remote Similarity |
NPD1375 |
Discontinued |
0.6978 |
Remote Similarity |
NPD9620 |
Approved |
0.6978 |
Remote Similarity |
NPD9621 |
Approved |
0.6978 |
Remote Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.6978 |
Remote Similarity |
NPD9619 |
Approved |
0.6974 |
Remote Similarity |
NPD1653 |
Approved |
0.6972 |
Remote Similarity |
NPD6663 |
Approved |
0.6968 |
Remote Similarity |
NPD2801 |
Approved |
0.6967 |
Remote Similarity |
NPD288 |
Approved |
0.6963 |
Remote Similarity |
NPD5846 |
Approved |
0.6963 |
Remote Similarity |
NPD6516 |
Phase 2 |
0.6963 |
Remote Similarity |
NPD5238 |
Clinical (unspecified phase) |
0.6959 |
Remote Similarity |
NPD4628 |
Phase 3 |
0.6957 |
Remote Similarity |
NPD8651 |
Approved |
0.6957 |
Remote Similarity |
NPD5311 |
Approved |
0.6957 |
Remote Similarity |
NPD5310 |
Approved |
0.6957 |
Remote Similarity |
NPD6696 |
Suspended |
0.6954 |
Remote Similarity |
NPD1512 |
Approved |
0.695 |
Remote Similarity |
NPD7095 |
Approved |
0.6944 |
Remote Similarity |
NPD823 |
Approved |
0.6944 |
Remote Similarity |
NPD6653 |
Approved |
0.6944 |
Remote Similarity |
NPD817 |
Approved |
0.6944 |
Remote Similarity |
NPD6353 |
Approved |
0.694 |
Remote Similarity |
NPD1182 |
Approved |
0.6939 |
Remote Similarity |
NPD7037 |
Approved |
0.6937 |
Remote Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.6935 |
Remote Similarity |
NPD289 |
Clinical (unspecified phase) |
0.6934 |
Remote Similarity |
NPD2233 |
Approved |
0.6934 |
Remote Similarity |
NPD1840 |
Phase 2 |
0.6934 |
Remote Similarity |
NPD2232 |
Approved |
0.6934 |
Remote Similarity |
NPD1608 |
Approved |
0.6934 |
Remote Similarity |
NPD2230 |
Approved |
0.6923 |
Remote Similarity |
NPD943 |
Approved |
0.6923 |
Remote Similarity |
NPD4140 |
Approved |
0.6913 |
Remote Similarity |
NPD2677 |
Approved |
0.6906 |
Remote Similarity |
NPD3055 |
Approved |
0.6906 |
Remote Similarity |
NPD3053 |
Approved |
0.6901 |
Remote Similarity |
NPD601 |
Approved |
0.6901 |
Remote Similarity |
NPD5111 |
Phase 2 |
0.6901 |
Remote Similarity |
NPD598 |
Approved |
0.6901 |
Remote Similarity |
NPD597 |
Approved |
0.6901 |
Remote Similarity |
NPD5110 |
Phase 2 |
0.6901 |
Remote Similarity |
NPD5109 |
Approved |
0.6897 |
Remote Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.6894 |
Remote Similarity |
NPD6166 |
Phase 2 |
0.6894 |
Remote Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.6894 |
Remote Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.6892 |
Remote Similarity |
NPD5177 |
Phase 3 |
0.6887 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6887 |
Remote Similarity |
NPD4123 |
Phase 3 |
0.6885 |
Remote Similarity |
NPD844 |
Approved |
0.6884 |
Remote Similarity |
NPD6582 |
Phase 2 |
0.6884 |
Remote Similarity |
NPD6583 |
Phase 3 |
0.6875 |
Remote Similarity |
NPD290 |
Approved |
0.6875 |
Remote Similarity |
NPD3657 |
Discovery |
0.6871 |
Remote Similarity |
NPD6004 |
Phase 3 |
0.6871 |
Remote Similarity |
NPD6005 |
Phase 3 |
0.6871 |
Remote Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.6871 |
Remote Similarity |
NPD6002 |
Phase 3 |
0.6871 |
Remote Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.6857 |
Remote Similarity |
NPD4624 |
Approved |
0.6853 |
Remote Similarity |
NPD6405 |
Approved |
0.6853 |
Remote Similarity |
NPD1130 |
Approved |
0.6853 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6853 |
Remote Similarity |
NPD2674 |
Phase 3 |
0.6853 |
Remote Similarity |
NPD6407 |
Approved |
0.6853 |
Remote Similarity |
NPD1136 |
Approved |
0.6853 |
Remote Similarity |
NPD1132 |
Approved |
0.6848 |
Remote Similarity |
NPD7240 |
Approved |
0.6846 |
Remote Similarity |
NPD3892 |
Phase 2 |
0.6842 |
Remote Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.6838 |
Remote Similarity |
NPD2932 |
Approved |
0.6838 |
Remote Similarity |
NPD3019 |
Approved |
0.6838 |
Remote Similarity |
NPD2668 |
Approved |
0.6838 |
Remote Similarity |
NPD2667 |
Approved |
0.6838 |
Remote Similarity |
NPD4059 |
Approved |
0.6826 |
Remote Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.6818 |
Remote Similarity |
NPD2229 |
Approved |
0.6818 |
Remote Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.6818 |
Remote Similarity |
NPD3455 |
Phase 2 |
0.6818 |
Remote Similarity |
NPD2228 |
Approved |
0.6818 |
Remote Similarity |
NPD2234 |
Approved |
0.6815 |
Remote Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.6815
|
Remote Similarity |
NPD2563 |
Approved |